Triple meeting – Mirati gets an edge over Amgen
Mirati’s Kras inhibitor looks better than Amgen’s on efficacy, but toxicity worries prevent a knockout punch.
Crispr valuation is no match for reality
A patient death overshadowed the first data from a human trial of the company’s allogeneic Car-T therapy CTX110.
SITC 2020 – embargo snafu triggers the first movers
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Bristol scores early
The first of several perioperative Opdivo trials is said to read out positively, reminding the markets of such settings’ importance.
